mCapOX plus cetuximab

Phase 3Monoclonal antibody

WWest China Hospital

mCapOX plus cetuximab is one of 71 small molecule programs targeting First-line Treatment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

First-Line TreatmentNot yet recruiting

MetastaticRecruiting

First-Line TreatmentPhase 3

Not yet recruiting

MetastaticPhase 2

Recruiting

Competition

Competitive Landscape

74 competitors in First-Line Treatment

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

4 2

Lexapro

AbbVie

Phase 3

1 3

Tuoyi

SSun Yat-sen University

Phase 3

6 4

Vepesid

AAvyxa

Phase 3

3 5

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

2 6

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 7

Effexor

WWyeth-Lederle Vaccines

Phase 3

1 8

Zoloft

VViatris Specialty LLC

Phase 3

1 9

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 10

Wellbutrin

GGlaxo Dba Glaxosmithkline

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Not yet recruiting

First-Line Treatment

NCT06616259

Clinical

Trials by Indication[1]

Metastatic1 trial

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

Recruiting·WWest China Hospital·Phase 2·NCT05022030·150 enrolled

First-line Treatment1 trial

First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study

Not yet recruiting·MMeng Qiu·Phase 3·NCT06616259·452 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for mCapOX plus cetuximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mCapOX plus cetuximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mCapOX plus cetuximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — West China Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: WWest China Hospital

mCapOX plus cetuximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Metastatic1 trial

First-line Treatment1 trial

References

Drug Info

Quick Facts

Related News